• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

CIDRAP- As mpox continues to circulate, US adults’ awareness of the virus has plummeted since 2022

Lance

MPH, CSP & CIT Retired, CHMM Emeritus

As mpox continues to circulate, US adults’ awareness of the virus has plummeted since 2022​

Laine Bergeson

30 minutes ago.
Mpox


Four years after a large global mpox outbreak, Americans’ awareness of the viral illness has dropped significantly, according to a survey today from the Annenberg Public Policy Center (APPC) at the University of Pennsylvania.

Of the 1,842 US adults surveyed from September 22 to October 5, 2026, only 8% said they had seen, read, or heard anything about mpox in the past month. That number is down from 11% in July 2024—and down 80% in July 2022.

While case counts have dropped nationwide over the past four years, the Centers for Disease Control and Prevention (CDC) says that “ongoing, low-level transmission has persisted,” which indicates “a transition toward endemic circulation.”

Mpox is transmitted by close contact with the scabs, rashes, or bodily fluids of an infected person. It can also be spread by contact with the clothing, bedding, towels, and dishes of an infected person. Sexual transmission is a common route.

Less than half know about mpox vaccine​

Roughly three-quarters (76%) of respondents said they are "not too familiar" or “not at all familiar” with mpox, and just 7% said they are “somewhat” or “very worried” about contracting it in the next three months. That number is significantly lower than the percentage of people (21%) who said they were worried about contracting it in August 2022.

Almost two-thirds (62%) said they were unsure about the contagiousness of mpox, and only 18% correctly said it is less contagious than COVID-19. In August 2022, 41% said they knew it was less contagious than COVID.

About half (49%) of survey respondents said they know how mpox is spread, while 51% recognized that face-to-face contact with an infected person increases the risk of infection. Those numbers are relatively unchanged from 2024.

As the epidemiology of mpox changes, public understanding of who is at risk, how the virus spreads, and how vaccination can protect against it needs to keep pace.
Knowledge about the mpox vaccine has dropped since August 2022, when 61% of people said they were aware that an mpox vaccine exists. Last month, less than half (44%) said they knew about the existence of an mpox vaccine. Forty-eight percent were unsure whether a vaccine exists.

“The persistence of these knowledge gaps matters because the virus has not stood still,” says APPC’s managing director of survey research, Ken Winneg, PhD, in an APPC news release. “As the epidemiology of mpox changes, public understanding of who is at risk, how the virus spreads, and how vaccination can protect against it needs to keep pace.”

Signs of progress, persistent misinformation​

While some misperceptions about mpox persist—16% of respondents said that the virus was definitely or probably bioengineered in a laboratory (a claim without evidence), and 7% incorrectly said that receiving the COVID vaccine increases the risk of getting mpox—the survey showed some signs of increased knowledge about the viral illness and openness to vaccination.

Nearly three quarters (73%) of respondents said they know that people with mpox should isolate until the rash is gone—an increase from 68% in 2024—and the same percentage of respondents said the benefits of being vaccinated against mpox outweigh the risks.

Sixty-nine percent of people said they would be “somewhat” or “very” likely to get an mpox vaccine if they were exposed to the virus, with the proportion who said they were “very” likely increasing, from 38% in 2024 to 44% last month.

The survey’s margin of error is plus or minus 3.2 percentage points.

 
Back
Top Bottom